BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (ROIV) today announced positive results from the induction period of the TUSCANY-2 Phase 2b ...
CAMBRIDGE, Mass., July 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NRSN) (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback